Boehringer Ingelheim

Boehringer Ingelheim Submits Marketing Authorisation Application to European Union and to the FDA for Investigational Anti-HIV Agent Tipranavir

Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...